All Pharmaceuticals articles – Page 4
-
News Brief
Pharmacy holding company CCO convicted in $50M Medicare fraud
Steven King, the chief compliance officer of a defunct pharmacy holding company, was found guilty of conspiracy to commit healthcare fraud and wire fraud for unnecessarily billing Medicare for more than $50 million in medical supplies.
-
Premium
CCO compensation survey: Big gains for energy, healthcare
Annual total compensation for chief compliance officers rose 10 percent in 2022, according to the latest compensation survey by executive search firm BarkerGilmore.
-
Blog
Eiger appoints general counsel, chief compliance officer
Eiger BioPharmaceuticals announced the appointment of James Vollins as general counsel, chief compliance officer, and corporate secretary.
-
News Brief
Ex-CCO of Rochester Drug Co-operative spared jail time after testifying
The former chief compliance officer of Rochester Drug Co-operative received no jail time after pleading guilty to aiding widescale opioid distribution and testifying against his former chief executive officer.
-
News Brief
DOJ intervenes in suit alleging Rite Aid helped fuel opioid crisis
The Department of Justice announced its intervention in a lawsuit alleging retail pharmacy chain Rite Aid filled hundreds of thousands of prescriptions for medically unnecessary oxycodone and other opioids in violation of multiple federal laws.
-
Blog
Catalent appoints general counsel, chief compliance officer
Catalent, a pharmaceuticals manufacturer and consumer health products company, announced the appointment of Joseph Ferraro as senior vice president, general counsel, chief compliance officer, and secretary.
-
News Brief
Walgreens to pay $7M for accepting alleged FCA violation proceeds
Walgreens agreed to pay $7 million to settle alleged violations of the False Claims Act that it overbilled the state of Tennessee’s Medicaid insurance program for Hepatitis C medications and kept the proceeds even after it discovered an employee’s misconduct.
-
Article
Walmart to pay $3.1B in nationwide opioid settlement
Walmart announced it agreed to a $3.1 billion nationwide settlement designed to resolve all the potential state lawsuits it faces for its alleged role in fueling the opioid epidemic.
-
Article
Ex-Mylan chief information officer charged over insider trading scheme
The chief information officer at former pharmaceutical company Mylan was charged with insider trading for tipping off a former colleague about the firm’s impending merger with a division of Pfizer, among other matters.
-
Article
DermaTran, other pharmacies settle with DOJ over pain cream false claims
DermaTran Health Solutions, its related pharmacy billing company, and three retail pharmacies agreed to pay more than $6.8 million to settle alleged violations of the False Claims Act for charging patients in federal health programs extra for pain relief creams.
-
Article
Pharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
-
Article
SEC charges pharma CEO, 2 companies with offering fraud
The Securities and Exchange Commission charged Paul Edalat and two pharmaceuticals companies he controlled—Sentar and Vivera—with engaging in a fraudulent investment scheme.
-
Premium
Experts: Where to start on your ESG journey
ESG directors from Tenneco and Amneal Pharmaceuticals shared best practices for businesses broaching the initial phases of environmental, social, and governance reporting at CW’s virtual ESG Summit.
-
Article
Akorn to pay $7.9M for Medicare false claims
Drug manufacturer Akorn Operating Company agreed to pay $7.9 million in a settlement with the Department of Justice for continuing to sell three drugs through Medicare when they were no longer covered under the program.
-
Article
Opioid cases against retail pharmacy chains yield compliance lessons
Two cases involving five retail pharmacy chains winding their way through court foretell a long and costly road ahead for all companies across the pharmaceutical supply chain battling litigation for their alleged roles in fueling the opioid epidemic.
-
Article
Bayer to pay $40M to settle long-running false claims suits
Bayer agreed to pay $40 million to settle allegations its sales team paid kickbacks to hospitals and doctors for prescribing its drugs and that the pharmaceuticals company downplayed risks regarding certain of its offerings.
-
Article
Mallinckrodt promotes VPs of compliance and legal to executive level
Mallinckrodt, a global pharmaceutical company, announced the promotions of its senior compliance and legal vice presidents to the executive level.
-
Article
Astellas promotes HR head to chief ethics and compliance officer
Pharmaceutical company Astellas announced the promotion of Head of Human Resources Katsuyoshi Sugita to chief people, ethics, and compliance officer, effective Oct. 1.
-
Article
SEC notifies five Chinese companies of HFCAA noncompliance
The Securities and Exchange Commission has notified five China-based public companies they could be delisted from U.S. stock exchanges if they do not allow their audits to be inspected by the Public Company Accounting Oversight Board.
-
Article
Mallinckrodt to pay $260M for False Claims Act violations
Pharmaceutical company Mallinckrodt agreed to pay approximately $260 million as part of a settlement announced by the Department of Justice for underpaying Medicaid rebates and violating kickback laws regarding its drug Acthar.